{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:39:40Z","timestamp":1787168380710,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Virtual Biotechnology Laboratory"},{"DOI":"10.13039\/100000015","name":"DOE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coronavirus CARES Act"},{"name":"Center for Structural Molecular Biology"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Structure"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.str.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T16:38:50Z","timestamp":1603471130000},"page":"1313-1320.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5789","authenticated-orcid":false,"given":"Daniel W.","family":"Kneller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-2568","authenticated-orcid":false,"given":"Stephanie","family":"Galanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-3825","authenticated-orcid":false,"given":"Gwyndalyn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh M.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-049X","authenticated-orcid":false,"given":"Leighton","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Kovalevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 2","key":"10.1016\/j.str.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2020.10.007_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main protease (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.str.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1099\/0022-1317-66-2-363","article-title":"Inhibition of the growth of human coronavirus 229E by leupeptin","volume":"66","author":"Appleyard","year":"1985","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.str.2020.10.007_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.abd2220","article-title":"COVID-19 and flu, a perfect storm","volume":"368","author":"Belongia","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.str.2020.10.007_bib5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.23899","article-title":"Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients","volume":"52","author":"de Bruijne","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.str.2020.10.007_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3390\/ijms21093099","article-title":"Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design","volume":"21","author":"Bzowka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.str.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.str.2020.10.007_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.str.2020.10.007_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"Pt 4","key":"10.1016\/j.str.2020.10.007_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. Section D"},{"key":"10.1016\/j.str.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"16247","DOI":"10.1073\/pnas.1111325108","article-title":"Accessing protein conformational ensembles using room-temperature X-ray crystallography","volume":"108","author":"Fraser","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.str.2020.10.007_bib13","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1074\/jbc.RA119.008725","article-title":"Productive reorientation of a bound oxime reactivator revealed in room temperature X-ray structures of native and VX-inhibited human acetylcholinesterase","volume":"294","author":"Gerlits","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib14","first-page":"64","article-title":"Viral cysteine proteases. Perspect","volume":"6","author":"Gorbalenya","year":"1996","journal-title":"Drug Discov. Des."},{"key":"10.1016\/j.str.2020.10.007_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 pandemic: a ccomprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control","volume":"9","author":"Helmy","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.str.2020.10.007_bib16","doi-asserted-by":"crossref","first-page":"104929","DOI":"10.1016\/j.phrs.2020.104929","article-title":"A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)","volume":"158","author":"Huang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.str.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1021\/bi036022q","article-title":"3C-like proteinase from SARS coronavirus Catalyzes substrate hydrolysis by a general base mechanism","volume":"43","author":"Huang","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.str.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.01044-16","article-title":"Pharmacokinetics of the new hapatitis C virus NS3 protease inhibitor narlaprevir following single-dose use with or without ritonavir in patients with liver cirrhosis","volume":"60","author":"Isakov","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.str.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib20","first-page":"1","article-title":"Old and re-purposed drugs for the treatment of COVID-19","author":"Jean","year":"2020","journal-title":"Exp. Rev. Anti-infect. Ther."},{"key":"10.1016\/j.str.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from COVID-19 virus and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.str.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.str.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14756366.2019.1690480","article-title":"Inhibition of SARS-CoV 3CL protease by flavonoids","volume":"35","author":"Jo","year":"2020","journal-title":"J.\u00a0Enz. Inhibit. Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.str.2014.04.016","article-title":"Crystal cryocooling distorts conformational heterogeneity in a model Michaelis complex of DHFR","volume":"22","author":"Keedy","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.str.2020.10.007_bib25","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2020.10.007_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.str.2018.01.006","article-title":"\u2018To be or not to be\u2019 protonated: atomic details of human carbonic anhydrase-clinical drug complexes by neutron crystallography and simulation","volume":"26","author":"Kovalevsky","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.str.2020.10.007_bib27","first-page":"862","article-title":"Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate","volume":"318","author":"Kuo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.str.2020.10.007_bib28","series-title":"HCV: The Journey from Discovery to a Cure. Topics in Medicinal Chemistry","first-page":"261","article-title":"Development and marketing of INCIVEK (telaprevir; VX-950): a first-generation HCV protease inhibitor, in Combination with PEGylated interferon and ribavirin","volume":"vol. 31","author":"Kwong","year":"2019"},{"key":"10.1016\/j.str.2020.10.007_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.str.2020.10.007_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cca.2020.05.044","article-title":"COVID-19:transmission, prevention, and potential therapeutic opportunities","volume":"508","author":"Lotfi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.str.2020.10.007_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.str.2020.10.007_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1515\/bchm3.1992.373.2.393","article-title":"Oxyanion hole interactions in serine and cysteine protease","volume":"373","author":"Menard","year":"1992","journal-title":"Biol. Chem. Hoppe-sayler"},{"key":"10.1016\/j.str.2020.10.007_bib33","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1601327113","article-title":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity","volume":"113","author":"Muramatsu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.str.2020.10.007_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03562-9","article-title":"Rescue of conformational dynamics in enzyme catalysis by directed evolution","volume":"9","author":"Otten","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2020.10.007_bib35","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib36","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1021\/jm060173k","volume":"50","author":"Prongay","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s13762-020-02781-2","article-title":"The novel coronavirus 2019-nCoV: its evolution and transmission into humans causing global COVID-19 pandemic","author":"Rastogi","year":"2020","journal-title":"Int. J. Environ. Sci. Technol."},{"key":"10.1016\/j.str.2020.10.007_bib38","doi-asserted-by":"crossref","first-page":"02832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatisis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLOS Pathol."},{"key":"10.1016\/j.str.2020.10.007_bib39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","article-title":"Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: desing, synthesis, biological evaluation, and docking studies","volume":"68","author":"Thanigaimalai","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib40","series-title":"HCV: The Journey from Discovery to a Cure. Topics in Medicinal Chemistry","first-page":"293","article-title":"Discovery of boceprevir, a ketoamide-derived HCV NS3 protease inhibitor, for treatment of genotype 1 infections","volume":"vol 31","author":"Venkatraman","year":"2019"},{"key":"10.1016\/j.str.2020.10.007_bib41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2017.05.045","article-title":"Discovery of unsymmetrical aromtic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study","volume":"137","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.str.2020.10.007_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.str.2020.10.007_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.str.2020.10.007_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/v12020244","article-title":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV","volume":"12","author":"Xu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.str.2020.10.007_bib45","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jmb.2006.11.073","article-title":"Production of authentic SARS-CoV Mpro with enzhanced activity: application as a novel tag-cleavage endopeptidase for protein overexpression","volume":"366","author":"Xue","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.str.2020.10.007_bib46","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Desing of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLOS Biol."},{"key":"10.1016\/j.str.2020.10.007_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"}],"container-title":["Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212620303798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212620303798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T02:38:29Z","timestamp":1760841509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969212620303798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0969212620303798"],"URL":"https:\/\/doi.org\/10.1016\/j.str.2020.10.007","relation":{},"ISSN":["0969-2126"],"issn-type":[{"value":"0969-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals","name":"articletitle","label":"Article Title"},{"value":"Structure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.str.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}